Fluocinolone Acetonide (Topical)
Brand names: Synalar, Synalar N (with neomycin), Synalar C (with clotrimazole)
Topical fluocinolone acetonide is a potent synthetic corticosteroid applied to the skin for inflammatory and pruritic dermatoses such as eczema and psoriasis that are unresponsive to milder steroids.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds intracellular glucocorticoid receptors to suppress release of inflammatory mediators, producing local anti-inflammatory, vasoconstrictive and antiproliferative effects in the skin.
Prescribing in practice
- As a potent topical steroid, prolonged or extensive use—especially under occlusion, on the face/flexures, or in children—risks skin atrophy, striae and systemic absorption, so apply thinly to the smallest effective area for the shortest time.
- Avoid use on untreated bacterial, fungal or viral skin infections unless combined with appropriate antimicrobial cover.
- Step down to a less potent preparation once the flare is controlled and review continued need.
Monitoring
Monitor the treated skin for signs of atrophy, telangiectasia or worsening infection, and reassess if there is no improvement within the expected period.
Counselling the patient
- Apply a thin layer only to the affected areas and wash hands afterwards unless the hands are being treated.
- Do not use on the face or skin folds for prolonged periods unless specifically advised.
- Continue any prescribed emollients, separating their application from the steroid.
Evidence & guidelines
Use of topical corticosteroids by potency and quantity (fingertip units) follows established NICE and MHRA guidance on safe topical steroid use.
Reference: BAD Topical Corticosteroid Guidelines; MHRA Drug Safety Update (2021); NICE NG10 (Psoriasis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD